We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sign up to read this article for FREE!

After signing up, you'll start to receive regular news updates from us.

Tecan and Technoclone; a Collaboration for the University Children’s Hospital in Zurich

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
Application specialists from Tecan have teamed up with Technoclone GmbH, Vienna, and the University Children’s Hospital in Zurich to validate the TECHNOTHROMBIN® thrombin generation assay (TGA) for Tecan’s Infinite® M200 multimode microplate reader.

Dr Oliver Speer, head of the Experimental Hematology and Erythrocyte Laboratory at the hospital, explained: “We installed the Infinite reader in our laboratory to standardize all of our photometric assays using just a single platform. Once we had completed the transfer of our existing assays to the Infinite, we realized that the flexibility and sensitivity of the instrument would allow us to supersede some of these assays with more efficient or sensitive methods, so became interested in the TECHNOTHROMBIN TGA.”

“Representatives from Tecan and Technoclone came to the hospital to assist with development and validation of this assay on the Infinite reader, enabling us to very quickly complete our validation study. The collaboration between the two companies was perfect for us, and we are still in regular contact with Tecan for technical assistance. The support we have received has been excellent, and Tecan has even developed the software specifically for our needs.”